PHARNEXT SCA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1497 EUR | -2.79% |
|
-17.75% | -92.52% |
| Mar. 06 | Pharnext: listing suspended pending further update | CF |
| Feb. 21 | Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing... |  |
| Sales 2021 | 3.56M 3.79M | Sales 2022 | 2.26M 2.4M | Capitalization | 26.1K 27.76K |
|---|---|---|---|---|---|
| Net income 2021 | -30M -31.9M | Net income 2022 | -38M -40.41M | EV / Sales 2021 | - |
| Net Debt 2021 | 14.24M 15.14M | Net Debt 2022 | 22.16M 23.56M | EV / Sales 2022 | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | 23 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.79% | ||
| 1 week | -17.75% | ||
| Current month | -40.12% | ||
| 1 month | -40.12% | ||
| 3 months | -85.03% | ||
| 6 months | -99.98% | ||
| Current year | -92.52% |
1 week
0.14
0.19
1 month
0.140.31
Current year
0.143.00
1 year
0.141 000 000.00
3 years
0.141 000 000.00
5 years
0.141 000 000.00
10 years
0.141 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | 22-11-07 |
| Founder | - | 06-12-31 | |
Melissa Israel
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Kuo
BRD | Director/Board Member | 58 | 22-06-15 |
| Director/Board Member | 76 | 20-07-16 | |
| Director/Board Member | 64 | 23-07-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.1497 | -2.79% | 68,645 |
| 24-04-17 | 0.154 | -2.28% | 21,883 |
| 24-04-16 | 0.1576 | -9.43% | 23,756 |
| 24-04-15 | 0.174 | -10.03% | 14,576 |
| 24-04-12 | 0.1934 | +6.26% | 25,694 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotes
Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
Sector
Pharmaceuticals
Calendar
2024-10-16
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -92.52% | 27.76K | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- ALPHA Stock
